Peculiarities of Etiology of Respiratory Virus Infections in Hospitalized Patients Depending on the Demographic, Socio-Economic Factors and Previous Vaccination

Etiology of respiratory virus infections among 1699 hospitalized patients (HP) was determined by PCR during the period of increased influenza activity in 2012 - 2013 season. The rate of accidence of influenza virus in dependence of gender, age, social and demographic factors and previous vaccination was analysed. Young children dominated in the age structure of HP, while the elderly were hospitalized very rarely. According to results obtained rate of influenza detection in HP was significantly higher among adults in comparison with children (63,5 and 30,7% of investigated patients, correspondingly). Respiratory syncytial virus and rhinoviruses were detected the most regularly (8.7 and 3.1%, correspondingly) in children, parainfluenza and adenoviruses were registered rarely (1.4 and 2.1%, correspondingly). Rate of detection of coronaviruses and bocavirus was low and varied in the range 0.3 - 0.6%. Indicated above ARI agents among hospitalized adults were detected rarely (0 - 1.5%) with exception of RSV which was detected among elderly (75 - 84 years) in 5.9% cases. No metapneumovirus cases were detected among HP in indicated period. Although males dominated (58%) among HP influenza cases, regardless of the type/subtype, were registered more frequently among girls in comparison with the boys of the same age groups. Influenza cases were registered more frequenly as well among smoking than in not smoking patients. Young children dominated in the age structure of HP, while the elderly were hospitalized very rarely.

грипп, респираторные инфекции, госпитализация, этиология, диагностика, вакцинация, influenza, respiratory infections, hospitalization, etiology, diagnosis, vaccination

1. Puig-Barberà J., Tormos A., Sominina A., Burtseva E., Launay O., Ciblak M. et al. First-year results of the Global Influenza Hospital Surveillance Network: 2012 – 2013. Northern hemisphere influenza season. BMC Public Health. 2014; 14: 564. Doi:10.1186/1471-2458-14-564.

2. Puig-Barbera J., Natividad-Sancho A., Launay O., Burtseva E., Ciblak M., Tormos A. et al. 2012−– 2013 seasonal influenza vaccine effectiveness against influenza hospitalization: results from the global influenza hospital surveillance network (GIHSN). PLOS. June 2014; 9 (6): 100497. Doi: 10.1371/journal.pone.0100497.

3. Ridenhour B.J., Campitelli M.A., Kwong J.C., Rosella L.C., Armstrong B.G., Mangtani P. et al. Effectiveness of inactivated influenza vaccines in preventing influenzaassociated deaths and hospitalizations among Ontario residents aged ≥ 65 years: estimates with generalized linear models accounting for healthy vaccinee effects. PLoS One. 2013 Oct 16; 8 (10): 76318. Doi: 10.1371.

4. Talbot H.K., Zhu Y., Chen Q., Williams J.V., Thompson M.G., Griffin M.R. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011 – 2012 influenza season. Clin Infect Dis. 2013 Jun; 6 (12): 1774 –− 1777. Doi: 10.1093.

5. Udell J.A., Zawi R., Bhatt D.L., Keshtkar-Jahromi M., Gaughran F., Phrommintikul A. et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013 Oct 23; 310 (16): 1711−– 1720. Doi: 10.1001/jama.2013.279206.

6. Nekrasov A.V., Puchkova N.G. Strategy of improvement and evaluation methods of influenza vaccines. Grippol® Plus – modern protection against influenza. Russian Medicl Journal (RMJ). 2008; 22: 1507−– 1509 (in Russian).

7. Voitsekhovskaya E.M., Vakin V.S., Vasilieva A.A., Kuznetsova E.V., Lonskaya N.I., El'shina G.A. et al. The results of the immunogenicity analysis of the new influenza vaccine Grippol® Plus. Epidemiologiya and Vaccinal Prevention. 2009; 1 (44): 40 – 45 (in Russian).

8. Khan A.S., Polezhaev F., Vasiljeva R., Drinevsky V., Buffington J., Gary H. et al. Comparison of US inactivated split-virus and Russian live attenuated, coldadapted trivalent influenza vaccines in Russian schoolchildren. J. Infect Dis. 1996 Feb; 173 (2): 453 – 456.

9. Zverev V.V., Kiselev O.I., Korovkin S.A., Mironov A.N., Melnikov S.J., Mikhailova N.A. et al. The clinical trial of a new inactivated influenza vaccine «Grifor®». J. Mikrobiology. 2009; 2: 35 – 40 (in Russian).

10. Kiselev O.I., Korovkin S.A., Mironov A.N., Mel'nikov S.Ya., Dyldina N.V., Erofeeva M.K. et al. Results of the clinical study of reactogenicity, safety and immunogenicity of the vaccine GRIFOR® in the elderly contingent (60 years and older). Epidemiologiya and Vaccinal Prevention. 2008; 4: 36 – 39 (in Russian).

11. Erofeeva M.K., Nikonorov I.Y., Maksakova V.L., El'shina G.A., Gorbunov M.A., Kraynova T.I. et al. Evaluating the effectiveness of influenza vaccine Grippol Plus in school-age children during the influenza epidemic of 2008 – 2009. Epidemiologiya and Vaccinal Prevention. 2010; 4 (53): 80 – 86 (in Russian).

12. WHO Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO; 2011: 153. ISBN 978924 1548090. http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf

13. Gualano R.C., Hansen M.J., Vlahos R., Jones J.E., Park-Jones R.A., Deliyannis G. et al. Cigarette smoke worsens lung inflammation and impairs resolution of influenza infection in mice. Respiratory Research. 2008; 9: 53. Doi: 10.1186/1465-9921-9-53.

14. Sominina A., Burtseva E., Eropkin M., Karpova L., Zarubaev V., Smorodintseva E. et al. Influenza surveillance in Russia based on epidemiological and laboratory data for the period from 2005 to 2012. American Journal of Infectious Diseases. 2013; 9 (3): 77 –− 93. Doi: 10.3844 ajidsp.2013.77.93.

15. Karpova L.S., Sominina A.A., Dmitrieva M.N., Popovtseva N.M., Stolyarova T.P., Kiselev O.I. Comparison of pandemic influenza in Russia 2009 – 2010. followed by epidemics with influenza A (H1N1) pdm09 (2011 – 2014). Epidemiologiya and Vaccinal Prevention. 2014; 6: 8 – 15 (in Russian).

16. Epstein M.A., Reynaldo S., Nelson El-Amin A. Is smoking a risk factor for influenza hospitalization and death? J. Infect. Dis. 2010; 201 (5): 794 – 795. Doi: 10.1086/650469.